ArticleJournal of pathology and translational medicine2020
Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer.
Article in Journal of pathology and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Prognostic significance and tumor cell interactions of tumor-associated neutrophils in gastric cancer.Molecular medicine (Cambridge, Mass.) · 2026Article
- MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.Nature communications · 2026Article
- Tumor-Associated Macrophage Infiltration and PD-L1 Expression in Gastric Cancer According to a Modified TCGA-Based Classification.Journal of gastric cancer · 2026Article
- Comparative study of clinical features, pathology, and immunophenotype between HIV-related cutaneous and visceral Kaposi's sarcoma.BMC cancer · 2026Article
- Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance.Molecular cancer · 2026Review
- Expression of p53 and p63 proteins and their correlation with histological grades among gastric carcinoma specimens at Mbarara Regional Referral Hospital.African journal of laboratory medicine · 2026Article
- Integrated bioinformatics and immunohistochemical analysis reveal that S100A16 is correlated with mutational burden, immune evasion, andInternational journal of clinical and experimental pathology · 2026Article
- Immunophenotypic Panel for Comprehensive Characterization of Aggressive Thyroid Carcinomas.Cells · 2025Article
- Correlation ofCurrent oncology (Toronto, Ont.) · 2025Article
- A Study of the Effectiveness of Apoptosis Biomarkers in the Diagnosis of Gastric Cancer in Kazakhstan: A Review of Systematic Evidence.Medical journal of the Islamic Republic of Iran · 2025Review
- Mutant Pattern of p53 as a Feasible Predictor of Distant Metastasis Following Curative Gastrectomy for Advanced-stage Gastric Cancer.Journal of Cancer · 2025Article
- Assessment of TP53 and CDKN2A status as predictive markers of malignant transformation of sinonasal inverted papilloma.Scientific reports · 2024Article
- The spectrum of TP53 mutations in Rwandan patients with gastric cancer.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2024Article
- CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.The Journal of biological chemistry · 2024Article
- Characterization on the oncogenic effect of the missense mutations of p53 via machine learning.Briefings in bioinformatics · 2023Article
- Dedifferentiated Endometrial Carcinoma: A Rare Aggressive Neoplasm-Clinical, Morphological and Immunohistochemical Features.Cancers · 2023Review
- Mutant pattern of p53 predicts local recurrence and poor survival rate in gastric cancer.Histology and histopathology · 2023Article
- Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2023Article
- p53/Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundRecently, molecular classifications of gastric cancer (GC) have been proposed that include TP53 mutations and their functional activity. We aimed to demonstrate the correlation between p53 immunohistochemistry (IHC) and TP53 mutations as well as their clinicopathological significance in GC.
methodsDeep targeted sequencing was performed using surgical or biopsy specimens from 120 patients with GC. IHC for p53 was performed and interpreted as strong, weak, or negative expression. In 18 cases (15.0%) with discrepant TP53 mutation and p53 IHC results, p53 IHC was repeated.
resultsStrong expression of p53 was associated with TP53 missense mutations, negative expression with other types of mutations, and weak expression with wild-type TP53 (p<.001). The sensitivity for each category was 90.9%, 79.0%, and 80.9%, and the specificity was 95.4%, 88.1%, and 92.3%, respectively. The TNM stage at initial diagnosis exhibited a significant correlation with both TP53 mutation type (p=.004) and p53 expression status (p=.029). The Kaplan-Meier survival analysis for 109 stage II and III GC cases showed that patients with TP53 missense mutations had worse overall survival than those in the wild-type and other mutation groups (p=.028). Strong expression of p53 was also associated with worse overall survival in comparison to negative and weak expression (p=.035).
conclusionsResults of IHC of the p53 protein may be used as a simple surrogate marker of TP53 mutations. However, negative expression of p53 and other types of mutations of TP53 should be carefully interpreted because of its lower sensitivity and different prognostic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.